Ribonucleic Acid (RNA) Splicing Modulators Global Market Report 2026

The ribonucleic acid (RNA) splicing modulators market size has grown rapidly in recent years. It will grow from $2.69 billion in 2025 to $3.12 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to increasing prevalence of genetic disorders, advancements in molecular biology techniques, growth of oncology therapeutics, rising r&d investments, adoption of antisense oligonucleotides.

The ribonucleic acid (RNA) splicing modulators market size is expected to see rapid growth in the next few years. It will grow to $5.69 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to development of ai-driven splicing modulators, expansion of personalized medicine approaches, increasing collaborations between pharma and biotech, advancements in delivery mechanisms, regulatory approvals for novel therapies. Major trends in the forecast period include targeted rna splicing therapies, personalized genetic medicine, high-throughput screening platforms, integration with bioinformatics tools, advanced molecular modelling.

The growing prevalence of genetic disorders is expected to propel the ribonucleic acid (RNA) splicing modulators market forward. Genetic disorders are conditions caused by DNA abnormalities, including mutations, deletions, or chromosomal changes, that disrupt normal biological functions. Increasing awareness and advanced diagnostics are leading to higher identification rates of genetic disorders, allowing earlier detection and management of inherited conditions. RNA splicing modulators aid in managing genetic disorders by targeting and correcting abnormal RNA splicing events, offering therapeutic potential to address genetic mutations responsible for these conditions. For instance, in May 2024, the National Health Service, a UK-based government department, reported that 17,000 people live with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed annually. Therefore, the rising prevalence of genetic disorders is fueling the growth of the ribonucleic acid (RNA) splicing modulators market.

Key companies operating in the ribonucleic acid (RNA) splicing modulators market are focusing on advancement in RNA-targeted drug discovery platforms, such as RNA‑directed small molecule splicing modulators, to improve efficacy, enhance safety, and address unmet needs in neurodegenerative diseases. RNA-directed small molecule splicing modulators are small compounds that bind RNA to alter pre-mRNA splicing, correcting or modifying splicing patterns to treat genetic diseases or cancers. For example, in September 2025, Skyhawk Therapeutics, a US‑based biotechnology company, announced positive interim data from its Phase 1 clinical trial of SKY-0515 for Huntington's disease. It is an orally administered, investigational small molecule RNA splicing modifier developed through the company's SKYSTAR platform. It demonstrated dose-dependent reductions of mutant huntingtin protein (up to 62%) and PMS1 mRNA in patients, with excellent brain penetration and a favorable safety profile, showcasing a potential dual-mechanism approach to target core pathogenic processes without operator intervention.

In October 2025, Novartis AG, a Switzerland-based healthcare company, acquired Avidity Biosciences Inc. for approximately $12 billion. Through this acquisition, Novartis intends to bolster its late-stage neuroscience pipeline and advance RNA therapeutics by integrating Avidity’s antibody oligonucleotide conjugates (AOCs) platform. Avidity Biosciences Inc. is a US-based company developing RNA-based therapies for rare neuromuscular diseases, focused on delivering targeted genetic medicines to muscle tissue for both government and commercial applications.

Major companies operating in the ribonucleic acid (RNA) splicing modulators market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Biogen Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Abivax SA, Twist Bioscience Corporation, Wave Life Sciences Ltd, Arrakis Therapeutics Inc., Remix Therapeutics Inc., Anima Biotech Inc., Rgenta Therapeutics Inc., Avidity Biosciences Inc., Skyhawk Therapeutics Inc., Stoke Therapeutics Inc., Accent Therapeutics Inc., Chordia Therapeutics Inc., Panorama Medicine Inc., Serna Therapeutics Inc., Ribometrix Inc., Envisagenics Inc., Dyne Therapeutics Inc.

North America was the largest region in the ribonucleic acid (RNA) splicing modulators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) splicing modulators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ribonucleic acid (RNA) splicing modulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA) splicing modulators market consists of sales of splice-switching oligonucleotides (SSOs), exon-skipping therapies, and RNA-binding small molecules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic acid (RNA) splicing modulators are therapeutic compounds that influence the splicing of pre-mRNA, the process that removes non-coding regions and joins coding regions to form mature RNA. They are employed to correct or adjust abnormal RNA splicing patterns linked to genetic disorders or cancers, thereby restoring proper protein function and addressing the underlying disease mechanisms.

The prominent product types of ribonucleic acid (RNA) splicing modulators include small molecule modulators, antisense oligonucleotides, small interfering RNA, and other variants. Small molecule modulators are compounds designed to influence RNA splicing processes, helping to correct gene expression and treat various diseases. They are administered via subcutaneous, intravenous, and intrathecal central nervous system-adjacent routes. Applications include cancer, genetic disorders, and neurological disorders, serving pharmaceutical companies, research institutes, hospitals and clinics, and other end users.

Tariffs have influenced the RNA splicing modulators market by raising import costs for small molecule modulators, antisense oligonucleotides, and siRNA products. This has particularly affected pharmaceutical companies and research institutes in regions like North America and Europe, which depend on global suppliers for advanced therapeutics. While tariffs increase costs and can delay product adoption, they are also prompting local manufacturing initiatives and innovation in cost-efficient production, which could strengthen regional capabilities and market resilience.

The ribonucleic acid (RNA) splicing modulators market research report is one of a series of new reports that provides ribonucleic acid (RNA) splicing modulators market statistics, including ribonucleic acid (RNA) splicing modulators industry global market size, regional shares, competitors with a ribonucleic acid (RNA) splicing modulators market share, detailed ribonucleic acid (RNA) splicing modulators market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (RNA) splicing modulators industry. This ribonucleic acid (RNA) splicing modulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.